The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease
Open accessAbstract
In view of its ability to explain the most frequent motor symptoms of Parkinson’s Disease (PD), degeneration of dopaminergic neurons has been considered one of the disease’s main pathophysiological features. Several studies have shown that neurodegeneration also affects noradrenergic, serotoninergic, cholinergic and other monoaminergic neuronal populations. In this work, the characteristics of cholinergic deficits in PD and their clinical correlates are reviewed. Important neurophysiological processes at the root of several motor and cognitive functions remit to cholinergic neurotransmission at the synaptic, pathway, and circuital levels. The bulk of evidence highlights the link between cholinergic alterations and PD motor symptoms, gait dysfunction, levodopa-induced dyskinesias, cognitive deterioration, psychosis, sleep abnormalities, autonomic dysfunction, and altered olfactory function. The pathophysiology of these symptoms is related to alteration of the cholinergic tone in the striatum and/or to degeneration of cholinergic nuclei, most importantly the nucleus basalis magnocellularis and the pedunculopontine nucleus. Several results suggest the clinical usefulness of antimuscarinic drugs for treating PD motor symptoms and of inhibitors of the enzyme acetylcholinesterase for the treatment of dementia. Data also suggest that these inhibitors and pedunculopontine nucleus deep-brain stimulation might also be effective in preventing falls. Finally, several drugs acting on nicotinic receptors have proved efficacious for treating levodopa-induced dyskinesias and cognitive impairment and as neuroprotective agents in PD animal models. Results in human patients are still lacking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506 · cited 1×
“These cellular pathologies are closely intertwined with one of the hallmarks of the disease, namely the abnormal accumulation of misfolded protein aggregates.(5) Lewy bodies constitute a characteristic pathological finding, second only to the neurofibrillary tangles in Alzheimer's disease (AD).”
BackgroundLoss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases
Hetz, C., & Mollereau, B. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3689 · Cited by 684
Nicotine amplifies reward-related dopamine signals in striatum
Rice, M. E., & Cragg, S. J. (2004) · Nature Neuroscience · doi:10.1038/nn1244 · Cited by 594
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
Raiteri, M., Leardi, R., & Marchi, M. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21528-2 · Cited by 314 · cited 1×
“Presynaptic mAChRs (M2, M4 subtypes) are largely inhibitory and perform this function partly as inhibitory autoreceptors on cholinergic terminals.(23) The M2 subtype is the predominant autoreceptor in the hippocampus and cerebral”
BackgroundOptogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep
Van Dort, C. J., Zachs, D. P., Kenny, J. D., Zheng, S., Goldblum, R. R., Gelwan, N. A., Ramos, D. M., Nolan, M. A., Wang, K., Weng, F.-J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423136112 · Cited by 296
Cholinergic deficits contribute to behavioral disturbance in patients with dementia
Minger, S. L., Esiri, M. M., McDonald, B., Keene, J., Carter, J., Hope, T., & Francis, P. T. (2000) · Neurology · doi:10.1212/wnl.55.10.1460 · Cited by 176 · cited 1×
“The greater the magnitude of depletion of cholinergic neurons and associated cholinergic pathways in cognitive-associated brain areas such as the neocortex and hippocampus, the more severe the associated dementia, suggesting a relationship between the clinical manifestations and the level of cholinergic decline.(102,1…”
BackgroundNicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Alkondon, M., Pereira, E. F. R., Barbosa, C. T. F., & Albuquerque, E. X. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37139-3 · Cited by 127
Bordia, T., Campos, C., Huang, L., & Quik, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140897 · Cited by 120
Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization
Bordia, T., Campos, C., McIntosh, J. M., & Quik, M. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162396 · Cited by 82 · cited 1×
“The mechanism by which nicotine might reduce LIDs was further explored in a study on 6OHDA-lesioned rats.(75) Interestingly, in addition to the already known antidyskinetic effect of nicotine, mecamylamine, a nicotinic receptor blocker, also reduced LIDs.”
Background
Cited by
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches
Bohnen, N. I., Yarnall, A. J., Weil, R. S., Moro, E., Moehle, M. S., Borghammer, P., Bedard, M.-A., & Albin, R. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00377-x · Cited by 293
Maurer, S. V., & Williams, C. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01489 · Cited by 260
Khatri, D. K., Preeti, K., Tonape, S., Bhattacharjee, S., Patel, M., Shah, S., Singh, P. K., Srivastava, S., Gugulothu, D., Vora, L., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x20666220507022701 · Cited by 75
Vignando, M., ffytche, D., Lewis, S. J. G., Lee, P. H., Chung, S. J., Weil, R. S., Hu, M. T., Mackay, C. E., Griffanti, L., Pins, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28087-0 · Cited by 42
Metadata
- Authors
- Perez-Lloret, S., & Barrantes, F. J.
- Venue
- npj Parkinson's Disease
- Published
- 2016-02-18
- Volume
- 2
- Issue
- 1
- Pages
- 16001-16001
- ISSN
- 2373-8057 (ISSN-L)
- OpenAlex
- W2594568835
- Cited by
- 210
- References
- 15
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.